JY
JANX icon

Jeff Yass’s Janux Therapeutics JANX Stock Holding History

Jeff Yass’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.4M Sell
156,500
-206,000
-57% -$2.98M ﹤0.01% 6069
2026
Q1 		$5.04M Buy
362,500
+62,000
+21% +$850K ﹤0.01% 4209
2025
Q4 		$4.15M Buy
300,500
+133,400
+80% +$3.14M ﹤0.01% 4326
2025
Q3 		$4.08M Buy
167,100
+64,800
+63% +$1.58M ﹤0.01% 4434
2025
Q2 		$2.36M Buy
102,300
+14,700
+17% +$387K ﹤0.01% 5436
2025
Q1 		$2.37M Sell
87,600
-135,500
-61% -$5.11M ﹤0.01% 5163
2024
Q4 		$11.9M Buy
223,100
+104,100
+87% +$5.51M ﹤0.01% 2438
2024
Q3 		$5.41M Buy
119,000
+50,600
+74% +$2.2M ﹤0.01% 3476
2024
Q2 		$2.87M Sell
68,400
-21,200
-24% -$995K ﹤0.01% 4403
2024
Q1 		$3.37M Buy
+89,600
New +$1.95M ﹤0.01% 4283

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Jeff Yass's JANX Position: Q2 2026 in Review

Jeff Yass sold out of Janux Therapeutics (JANX) in Q2 2026, closing a stake of 119,055 shares — an estimated $1.72M sold.

Jeff Yass first reported a position in JANX in Q1 2023 and held it in 10 quarters. The position peaked at $9.96M in Q1 2025. 196 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • Jeff Yass reported no remaining Janux Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jeff Yass sold 119,055 Janux Therapeutics shares in Q2 2026, an estimated $1.72M.
  • Jeff Yass first reported a position in Janux Therapeutics in Q1 2023 and held it in 10 quarters.
  • Jeff Yass's Janux Therapeutics position peaked at $9.96M in Q1 2025.
  • 196 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.